These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11426656)

  • 1. New agents in cancer clinical trials.
    Adams J; Elliott PJ
    Oncogene; 2000 Dec; 19(56):6687-92. PubMed ID: 11426656
    [No Abstract]   [Full Text] [Related]  

  • 2. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
    Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
    Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel molecular targeted therapies for refractory thyroid cancer.
    Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
    Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Perspectives on the oncologist pharmacopoeia].
    Lansiaux A; Bailly C
    Bull Cancer; 2003 Jan; 90(1):25-30. PubMed ID: 12609801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances of molecular targeted agents: opportunities for imaging.
    Dancey JE
    Cancer Biol Ther; 2003; 2(6):601-9. PubMed ID: 14688462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
    Hawkins LM; Jayanthan AA; Narendran A
    Pediatr Res; 2005 Mar; 57(3):430-7. PubMed ID: 15659698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer treatment. New drugs, new hope.
    Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447
    [No Abstract]   [Full Text] [Related]  

  • 8. Researchers optimistic about sea change in cancer treatment.
    Stephenson J
    JAMA; 2001 Jun; 285(22):2841-2. PubMed ID: 11401587
    [No Abstract]   [Full Text] [Related]  

  • 9. Combinations of targeted therapies take aim at multiple pathways.
    Goldman B
    J Natl Cancer Inst; 2003 Nov; 95(22):1656-7. PubMed ID: 14625255
    [No Abstract]   [Full Text] [Related]  

  • 10. A new era in cancer therapeutics?
    Westwell AD
    Drug Discov Today; 2003 Jan; 8(2):64-5. PubMed ID: 12565007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic strategies for soft tissue sarcomas.
    von Mehren M
    Curr Treat Options Oncol; 2003 Dec; 4(6):441-51. PubMed ID: 14585225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic lethality: killing cancer with cancer.
    Garber K
    J Natl Cancer Inst; 2002 Nov; 94(22):1666-8. PubMed ID: 12441317
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple myeloma therapies.
    Strobeck M
    Nat Rev Drug Discov; 2007 Mar; 6(3):181-2. PubMed ID: 17396289
    [No Abstract]   [Full Text] [Related]  

  • 14. Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
    Patel SR
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1789-93. PubMed ID: 12457438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovations in antineoplastic therapy.
    Kaplow R
    Nurs Clin North Am; 2005 Mar; 40(1):77-94. PubMed ID: 15733948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gold standard or wrong standard?
    Oldham R; Dillman R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):271-2. PubMed ID: 15285873
    [No Abstract]   [Full Text] [Related]  

  • 18. [Molecular-targeted therapy for hormone-refractory prostate cancer].
    Nishimura K; Takayama H; Nakayama M; Nonomura N; Okuyama A
    Hinyokika Kiyo; 2006 Jun; 52(6):487-90. PubMed ID: 16848363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bortezomib in second-line therapy].
    Musch A
    Med Monatsschr Pharm; 2005 Sep; 28(9):332-3. PubMed ID: 16163891
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report.
    Sanford M; Scott LJ
    BioDrugs; 2011 Jun; 25(3):191-2. PubMed ID: 21627342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.